Myriad Genetics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYGN research report →
Range $3.6 – $8
Price Chart
About the company
Myriad Genetics, Inc. , a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics.
- CEO
- Samraat S. Raha
- IPO
- 1995
- Employees
- 2,700
- HQ
- Salt Lake City, UT, US
Get TickerSpark's AI analysis on MYGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $523.74M
- P/E
- -4.06
- PEG
- -0.09
- P/S
- 0.66
- P/B
- 1.97
- EV/EBITDA
- -8.46
- Div Yield
- 0.00%
- Gross Margin
- 68.33%
- Op Margin
- -14.34%
- Net Margin
- -16.07%
- ROE
- -40.40%
- ROIC
- -24.01%
Latest fiscal year · YoY change
- Revenue
- $824.50M-1.6%
- Gross Profit
- $576.60M-1.5%
- Op Income
- $-67,800,000
- Net Income
- $-365,900,000-187.4%
- EPS
- $-3.96-180.9%
- OCF Growth
- +120.7%
- FCF Growth
- +33.3%
- 52W High
- $8.09
- 52W Low
- $2.74
- 50D MA
- $4.93
- 200D MA
- $4.61
- Beta
- 1.61
- RSI (14)
- 49
- Avg Volume
- 2.26M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Myriad said Q3 improved sequentially on better revenue per test and stronger execution, and it raised full-year revenue guidance while advancing the planned sale of its Prenatal Health business.· November 4, 2026
- Q3 revenue was $202.7 million, down 1% year over year but up 6% sequentially, with adjusted EPS of negative $0.11 and adjusted EBITDA loss of $5 million.
- Gross margin improved to 67.9%, up 130 basis points sequentially, helped by a 1% year-over-year increase in average revenue per test.
- Cancer Care Continuum and Mental Health showed growth, while Prenatal Health remained weak; Prenatal revenue fell 12% year over year.
- Management said it signed a definitive agreement to sell Prenatal Health to Labcorp for $210 million plus inventory, valuing the unit at 1.3x trailing 12-month revenue.
- Full-year 2026 revenue guidance was raised modestly to $780 million-$790 million, with midpoint increased to $785 million.
- Management said HCT reimbursement pressure persists, but Q3 showed early progress from revenue cycle and market access initiatives.
Myriad reported third-quarter 2026 revenue of $202.7 million, down 1% year over year and up 6% sequentially. Adjusted EPS was negative $0.11, and adjusted EBITDA was a loss of $5 million. Gross margin was 67.9%, up 130 basis points sequentially but down 200 basis points year over year. Average revenue per test increased 1% year over year and 7% sequentially. By segment, Cancer Care Continuum revenue was $124 million, up 1% year over year; GeneSight revenue was $40 million, up 2%; and Prenatal Health revenue was $39 million, down 12%. Management raised full-year 2026 revenue guidance to $780 million-$790 million, with midpoint moved to $785 million from $780 million, citing stronger Q3 performance and improving average revenue per test, partly offset by potential Prenatal softness in Q4. The company also said it expects separate 2026 revenue guidance for Prenatal Health and for the Cancer Care Continuum and Mental Health businesses.
Samraat Raha framed the quarter as evidence that the company is taking decisive actions to address softness in Prenatal Health and reimbursement pressure in hereditary cancer testing. He emphasized the planned Prenatal divestiture, the Ascend initiative to modernize operations, and improved commercial execution as key pillars for a more focused Myriad. His tone was constructive and cautiously optimistic, with repeated references to building a stronger financial profile and better positioning the company for 2027.
Ben Wheeler highlighted the financial mechanics behind the quarter: revenue of $202.7 million, gross margin of 67.9%, adjusted EBITDA loss of $5 million, and adjusted EPS loss of $0.11. He said the HCT ASP softness was mainly driven by increased zero-pay and denials rather than contract changes or medical policy changes, and he pointed to early gains from revenue cycle optimization and MyRisk reimbursement efforts. He also said available capital was approximately $182 million, and that proceeds from the Prenatal sale could be used for debt reduction, internal and external growth investments, and other corporate purposes.
Analysts focused heavily on hereditary cancer pricing and guidance. Management said HCT average revenue per test pressure is mainly due to denials and revenue-cycle friction, not lower contracted rates, and described long-term average pressure of about 1% to 5%, with some periods skewing 3% to 5%. On the full-year guide, management said the higher midpoint mainly reflects the Q3 revenue beat and some expected Prenatal softness in Q4, and it said out-of-period or change-in-estimate adjustments were insignificant. In response to questions about the post-divestiture company, management said revenue growth should improve by more than 100 basis points and gross margin by more than 500 basis points, with meaningful progress on profitability expected in 2027.
The call showed sequential operational improvement, especially in average revenue per test and gross margin, suggesting the company’s reimbursement actions are starting to help. Management also sounded encouraged by Cancer Care Continuum volume growth, GeneSight growth, and the strategic simplification from selling Prenatal Health. The balance sheet should improve materially from the $210 million plus inventory cash deal, giving the company more flexibility to invest or repay debt.
The company is still dealing with reimbursement pressure in hereditary cancer testing, including more zero-pay and denials, and management explicitly expects ongoing modest headwinds to ASP over time. Prenatal Health remains a drag, with revenue down 12% in Q3 and management lowering near-term expectations for Q4 around the sale announcement. Management also said Precise MRD reimbursement is not expected until 2027, so that growth driver is still early and must be prudently managed until coverage is established.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 92.6%
- Shares Outstanding
- 95.92M
- Float Shares
- 88.86M
of shares held by institutions
203 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 15.92M | ▲ 5.03M |
| Vanguard Group Inc | 8.23M | ▲ 342.86K |
| Millennium Management LLC | 6.62M | ▼ 48.45K |
| Vestal Point Capital, LP | 5.74M | ▲ 4.09M |
| State Street Corp | 4.80M | ▼ 186.43K |
| D. E. Shaw & Co., Inc. | 4.58M | ▲ 82.36K |
| Vanguard Capital Management LLC | 4.00M | ▼ 77.56K |
| Acadian Asset Management LLC | 3.46M | ▲ 331.24K |
| Vanguard Portfolio Management LLC | 2.84M | ▼ 243.14K |
| Aqr Capital Management LLC | 2.77M | ▲ 854.39K |
| Mackenzie Financial Corp | 2.50M | ▲ 963.65K |
| Marshall Wace, Llp | 2.07M | ▲ 849.74K |
Held by 206 ETFs
Biggest fund positions in MYGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Davis Mark Steven | sell | 6,100 |
| Nov 6, 26 | Jampa Raj | other | 58,560 |
| Nov 6, 26 | Sikri Vishal | other | 53,236 |
| Nov 6, 26 | Solaiman Shereen | other | 83,049 |
| Nov 6, 26 | Fox Jennifer Lynne | other | 139,267 |
| Nov 6, 26 | Muzzey Dale | other | 92,632 |
| Nov 6, 26 | Verratti Mark | other | 146,933 |
| Nov 6, 26 | Wheeler Benjamin Richard | other | 121,379 |
| Nov 1, 26 | Fox Jennifer Lynne | other | 39,370 |
| Sep 21, 26 | Wheeler Benjamin Richard | other | 2,555 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MYGN coverage
Recent articles, reports, and earnings notes.
No research on MYGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MYGN report →Myriad Genetics Expands SRL Partnership in Japan to Support Future Growth
globenewswire.com · Nov 17
Myriad Genetics, Inc. (MYGN) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
Myriad Genetics, Inc. (MYGN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 4
Myriad Genetics Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
globenewswire.com · Nov 4
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
globenewswire.com · Nov 2
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
globenewswire.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.